Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - PAR GLAXO LAWSUIT

Par loses ondansetron case to GSK

 

BY OUR PHARMA CORRESPONDENT

13th August, 2005:The US District Court for the District of New Jersey ruled that two of GlaxoSmithKline's patents for ondansetron are valid, enforceable and infringed by Par's wholly-owned subsidiary, Kali Laboratories, Par Pharmaceutical Companies reported.

Kali’s ondansetron is the generic form of GlaxoSmithKline's Zofran ODT orally disintegrating tablets used for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, certain radiotherapies, and the prevention of postoperative nausea and/or vomiting. Annual US sales of Zofran ODT are approximately $225 million.
The two patents expire on 16th August 2005 and 24th December 2006, following the expiration of paediatric exclusivity.
Kali intends to appeal the decision, Par said.

Kali filed an ANDA with a Paragraph IV certificate with the FDA for the drug in September 2002, and this was accepted by the agency in October 2002. In October 2002, Kali’s ANDA was accepted for filing by the FDA. GlaxoSmithKline did not file suit against Kali on U.S. Patent Nos. 5955488 and 6063802, which expire in May 2016.

Kali was also the first to file on these composition patents and may be entitled up to 180 days of marketing exclusivity for the product. The 628 method of use patent expires August 16, 2005 and the 789 method of use patent expires December 24, 2006, following expiration of pediatric exclusivity, Par said. Par expects ondansetron hydrochloride (HCl) orally disintegrating tablets (ODT) to be launched no later than December 2006.
Under the terms of Kali’s agreement with Pliva, Inc., Pliva has exclusive rights to market, sell and distribute ondansetron HCl ODT in the US. The product will be manufactured by Kali and the companies will split profits from the sales of the product.

In June 2005, the FDA granted tentative approval for the company’s ANDA for ondansetron HCl ODT in 4 mg and 8 mg strengths. A tentative approval reflects the FDA’s preliminary determination that a generic product satisfies the substantive requirements for approval, subject to the expiration of any patents or exclusivity periods accorded to the reference listed drug. A tentative approval does not allow the applicant to market the generic product and postpones the final approval until all patent/exclusivity issues have expired.

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc. The company is also developing an additional line of branded pharmaceutical products for specialty markets, the first of which is Megace ES. Par currently manufactures, markets or licenses more than 90 prescription drugs.

GlaxoSmithKline (GSK) is a leading research-based pharmaceutical company. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.

GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.

The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
Based on 2004 Annual Results, GSK had sales of £20.3 billion ($37.2 billion) and profit before tax of £6.1 billion ($11.1 billion). Total pharmaceutical turnover was just over £17 billion ($31 billion) and consumer healthcare turnover was £3.2 billion ($5.8 billion).

GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Around 35,000 employees work at 82 manufacturing sites in 37 countries and over 15,000 are in R&D. GSK’s R&D is based at 24 sites in 11 countries with a budget of about £2.8bn/$5bn.

BY OUR PHARMA CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us